Journey Medical (DERM) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Journey Medical (DERM) over the past year, gaining 3.0% versus a loss of 55.8%. Over five years, DERM leads with a -61.1% price change compared with -92.5% for PDSB. PDS Biotechnology is the larger company by market cap ($95.4 million vs $93.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | PDSB |
|---|---|---|
| Share price | $3.30 | $0.7774 |
| Market cap | $93.16M | $95.39M |
| 1-day change | -7.04% | -3.70% |
| YTD return | -57.20% | +0.96% |
| 1-year return | -55.76% | +2.97% |
| 5-year return | -61.13% | -92.46% |
| EPS (TTM) | $-0.18 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $61.86M | — |
| Revenue growth (YoY) | +10.20% | — |
| Net income (latest FY) | $-11.43M | $-34.50M |
| Gross margin | 66.17% | — |
| Operating margin | -13.21% | — |
| Net margin | -18.48% | — |
| 52-week high | $9.56 | $1.79 |
| 52-week low | $3.21 | $0.195 |
| Distance from 52-week high | -65.46% | -56.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +286.36% | +478.85% |
| Average volume | 190.39K | 25.64M |
| Shares outstanding | 22.23M | 122.70M |
| Employees | 58 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed DERM by 58.7 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
DERM vs PDSB FAQ
Which is bigger, Journey Medical or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $95.39M compared with $93.16M for Journey Medical (DERM).
Which stock has performed better over the past year, DERM or PDSB?
PDSB returned +2.97% over the past 12 months, compared with -55.76% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.